NCT07349771: Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

Sponsor: Mayo Clinic. Phase: PHASE2. Conditions: Hematopoietic and Lymphatic System Neoplasm